{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T03:21:49Z","timestamp":1760239309737,"version":"build-2065373602"},"reference-count":42,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,10,25]],"date-time":"2020-10-25T00:00:00Z","timestamp":1603584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["08A1-IVPP12-014"],"award-info":[{"award-number":["08A1-IVPP12-014"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST102-2321-B-400\u2212022"],"award-info":[{"award-number":["MOST102-2321-B-400\u2212022"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The embryonated egg-based platform currently produces the majority of seasonal influenza vaccines by employing a well-developed master donor virus (MDV, A\/PR\/8\/34 (PR8)) to generate high-growth reassortants (HGRs) for A\/H1N1 and A\/H3N2 subtypes. Although the egg-based platform can supply enough seasonal influenza vaccines, it cannot meet surging demands during influenza pandemics. Therefore, multi-purpose platforms are desirable for pandemic preparedness. The Vero cell-based production platform is widely used for human vaccines and could be a potential multi-purpose platform for pandemic influenza vaccines. However, many wild-type and egg-derived influenza viruses cannot grow efficiently in Vero cells. Therefore, it is critical to develop Vero cell-derived high-growth MDVs for pandemic preparedness. In this study, we evaluated two in-house MDVs (Vero-15 and VB5) and two external MDVs (PR8 and PR8-HY) to generate Vero cell-derived HGRs for five avian influenza viruses (AIVs) with pandemic potentials (H5N1 clade 2.3.4, H5N1 clade 2.3.2.1, American-lineage H5N2, H7N9 first wave and H7N9 fifth wave). Overall, no single MDV could generate HGRs for all five AIVs, but this goal could be achieved by employing two in-house MDVs (vB5 and Vero-15). In immunization studies, mice received two doses of Vero cell-derived inactivated H5N1 and H7N9 whole virus antigens adjuvanted with alum and developed robust antibody responses.<\/jats:p>","DOI":"10.3390\/vaccines8040626","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T02:34:54Z","timestamp":1603679694000},"page":"626","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development and Evaluation of Vero Cell-Derived Master Donor Viruses for Influenza Pandemic Preparedness"],"prefix":"10.3390","volume":"8","author":[{"given":"Po-Ling","family":"Chen","sequence":"first","affiliation":[{"name":"National Institution of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Zhunan, Miaoli 35053, Taiwan"},{"name":"Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu 300044, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsai-Teng","family":"Tzeng","sequence":"additional","affiliation":[{"name":"National Institution of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Zhunan, Miaoli 35053, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan Yung-Chih","family":"Hu","sequence":"additional","affiliation":[{"name":"National Institution of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Zhunan, Miaoli 35053, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0659-0139","authenticated-orcid":false,"given":"Lily Hui-Ching","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Cellular Biology, National Tsing Hua University, Hsinchu 300044, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min-Shi","family":"Lee","sequence":"additional","affiliation":[{"name":"National Institution of Infectious Diseases and Vaccinology, National Health Research Institutes (NHRI), Zhunan, Miaoli 35053, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.vaccine.2010.04.083","article-title":"Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets","volume":"28","author":"Partridge","year":"2010","journal-title":"Vaccine"},{"key":"ref_2","unstructured":"U.S. Department of Health and Human Services (2017, June 15). Pandemic Influenza Plan, Available online: https:\/\/www.cdc.gov\/flu\/pandemic-resources\/pdf\/pan-flu-report-2017v2.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41541-018-0079-z","article-title":"Cell culture-derived influenza vaccines in the severe 2017-2018 epidemic season: A step towards improved influenza vaccine effectiveness","volume":"3","author":"Barr","year":"2018","journal-title":"NPJ Vaccines"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.tim.2011.12.002","article-title":"A cell-based backup to speed up pandemic influenza vaccine production","volume":"20","author":"Lee","year":"2012","journal-title":"Trends Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14760584.2017.1357471","article-title":"Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases","volume":"16","author":"Barrett","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tseng, Y.F., Hu, A.Y., Huang, M.L., Yeh, W.Z., Weng, T.C., Chen, Y.S., Chong, P., and Lee, M.S. (2011). Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: Implications for pandemic preparedness. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024057"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Chen, P.L., Hu, A.Y., Lin, C.Y., Weng, T.C., Lai, C.C., Tseng, Y.F., Cheng, M.C., Chia, M.Y., Lin, W.C., and Yeh, C.T. (2019). Development of American-Lineage Influenza H5N2 Reassortant Vaccine Viruses for Pandemic Preparedness. Viruses, 11.","DOI":"10.3390\/v11060543"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8148","DOI":"10.1038\/ncomms9148","article-title":"Development of high-yield influenza A virus vaccine viruses","volume":"6","author":"Ping","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s007050170002","article-title":"Universal primer set for the full-length amplification of all influenza A viruses","volume":"146","author":"Hoffmann","year":"2001","journal-title":"Arch. Virol."},{"key":"ref_10","unstructured":"WHO (2002, July 12). WHO Manual on Animal Influenza Diagnosis and Surveillance. Available online: http:\/\/www.who.int\/csr\/resources\/publications\/influenza\/en\/whocdscsrncs20025rev.pdf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.biologicals.2007.10.002","article-title":"Monitoring influenza virus content in vaccine production: Precise assays for the quantitation of hemagglutination and neuraminidase activity","volume":"36","author":"Kalbfuss","year":"2008","journal-title":"Biologicals"},{"key":"ref_12","first-page":"223","article-title":"A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines","volume":"52","author":"Schild","year":"1975","journal-title":"Bull. World Health Organ."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1080\/21645515.2020.1721223","article-title":"Development and characterization of standard reagents for cell-based prepandemic influenza vaccine products","volume":"16","author":"Lai","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1007\/s00253-016-7542-4","article-title":"Influenza virus intracellular replication dynamics, release kinetics, and particle morphology during propagation in MDCK cells","volume":"100","author":"Frensing","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10502","DOI":"10.1128\/JVI.00970-08","article-title":"Growth determinants for H5N1 influenza vaccine seed viruses in MDCK cells","volume":"82","author":"Murakami","year":"2008","journal-title":"J. Virol."},{"key":"ref_16","first-page":"233","article-title":"Development of serum-free media for cell growth and production of viruses\/viral vaccines--safety issues of animal products used in serum-free media","volume":"111","author":"Merten","year":"2002","journal-title":"Dev. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"254","DOI":"10.15585\/mmwr.mm6609e2","article-title":"Increase in Human Infections with Avian Influenza A(H7N9) Virus During the Fifth Epidemic\u2014China, October 2016\u2013February 2017","volume":"66","author":"Iuliano","year":"2017","journal-title":"MMWR Morb. Mortal. Wkly.. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12929-020-00645-y","article-title":"Development of high-growth influenza H7N9 prepandemic candidate vaccine viruses in suspension MDCK cells","volume":"27","author":"Tzeng","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1080\/21645515.2018.1460297","article-title":"Cell culture-derived flu vaccine: Present and future","volume":"14","author":"Eiros","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1016\/j.vaccine.2008.08.015","article-title":"Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines","volume":"26","author":"Hu","year":"2008","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hu, A.Y., Tseng, Y.F., Weng, T.C., Liao, C.C., Wu, J., Chou, A.H., Chao, H.J., Gu, A., Chen, J., and Lin, S.C. (2011). Production of inactivated influenza H5N1 vaccines from MDCK cells in serum-free medium. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0014578"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jmii.2019.03.009","article-title":"The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine\u2014A phase I randomized clinical trial","volume":"52","author":"Cheng","year":"2019","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8888","DOI":"10.1016\/j.vaccine.2011.09.069","article-title":"Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus","volume":"29","author":"Santiago","year":"2011","journal-title":"Vaccine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virusres.2015.01.007","article-title":"H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus","volume":"200","author":"Ren","year":"2015","journal-title":"Virus Res."},{"key":"ref_25","first-page":"1235","article-title":"Intranasal vaccination with a plant-derived H5 HA vaccine protects mice and ferrets against highly pathogenic avian influenza virus challenge","volume":"11","author":"Major","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Chia, M.Y., Hu, A.Y., Tseng, Y.F., Weng, T.C., Lai, C.C., Lin, J.Y., Chen, P.L., Wang, Y.F., Chao, S.R., and Chang, J.Y. (2015). Evaluation of MDCK cell-derived influenza H7N9 vaccine candidates in ferrets. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120793"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1016\/j.vaccine.2017.06.044","article-title":"Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I\/II, prospective, randomized, open-label trial","volume":"35","author":"Wu","year":"2017","journal-title":"Vaccine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3201\/eid2108.141086","article-title":"Development of Framework for Assessing Influenza Virus Pandemic Risk","volume":"21","author":"Trock","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1473-3099(15)00378-3","article-title":"H7N9 live attenuated influenza vaccine in healthy adults: A randomised, double-blind, placebo-controlled, phase 1 trial","volume":"16","author":"Rudenko","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e00502","DOI":"10.1128\/mSphere.00502-17","article-title":"Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans","volume":"2","author":"Stadlbauer","year":"2017","journal-title":"mSphere"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/infdis\/jiw414","article-title":"Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults","volume":"214","author":"Madan","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.2014.12854","article-title":"Serological responses to an avian influenza A\/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: A randomized clinical trial","volume":"312","author":"Mulligan","year":"2014","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.bbrc.2012.04.101","article-title":"High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avian influenza virus H5N1","volume":"421","author":"Zhou","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/jmv.24558","article-title":"Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment","volume":"88","author":"Yu","year":"2016","journal-title":"J. Med. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/21645515.2016.1231261","article-title":"Reassortment of high-yield influenza viruses in vero cells and safety assessment as candidate vaccine strains","volume":"13","author":"Zhou","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.vaccine.2014.11.007","article-title":"A Vero-cell-adapted vaccine donor strain of influenza A virus generated by serial passages","volume":"33","author":"Hu","year":"2015","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1128\/JVI.78.4.1851-1857.2004","article-title":"Generation of High-Yielding Influenza A Viruses in African Green Monkey Kidney (Vero) Cells by Reverse Genetics","volume":"78","author":"Ozaki","year":"2004","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.virol.2015.03.004","article-title":"A single NS2 mutation of K86R promotes PR8 vaccine donor virus growth in Vero cells","volume":"482","author":"Zhang","year":"2015","journal-title":"Virology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2016.10.008","article-title":"Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines","volume":"500","author":"Nogales","year":"2017","journal-title":"Virology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"10293","DOI":"10.1128\/JVI.01131-12","article-title":"NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge","volume":"86","author":"Pica","year":"2012","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1128\/JVI.72.8.6437-6441.1998","article-title":"Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells","volume":"72","author":"Egorov","year":"1998","journal-title":"J. Virol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/626\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:27:56Z","timestamp":1760178476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/4\/626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,25]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["vaccines8040626"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8040626","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2020,10,25]]}}}